Chemotherapy-induced nausea and vomiting:: pathophysiology and therapeutic principles

• Autores: Juan Bayo Calero, P. Jiménez Fonseca, Susana Hernando Polo, Sònia Servitja Tormo, Aitana Calvo Ferrándiz, Sandra Falagán Martínez, Estefanía García Pérez, Iria González Maeso, María José de Miguel Peláez, Quionia Pérez Arnillas, Ana Milena Roldan, Antonio Ruiz Fernández, Agustí Barnadas i Molins
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 14, Nº. 6, 2012, págs. 413-422
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Chemotherapy-induced nausea and vomiting (CINV) is a major determinant of quality of life in cancer patients. In addition, the perceptions that oncology professionals have about CINV quite often do not coincide with reality. Antineoplastic agents and their combinations can be categorised according to their emetogenic level, and this categorisation is helpful for classifying the severity of CINV and treating it. All CINV treatment guidelines emphasise the need to administer prophylaxis to patients who receive highly or moderately emetogenic chemotherapy. With the introduction of NK1 receptor antagonists, the control of acute and delayed CINV after highly or moderately emetogenic chemotherapy schedules has improved in the great majority of patients. NK1 receptor antagonists have been demonstrated to improve the control of CINV in all risk subgroups of patients.